TAVI et al

Question 1

Life expectancy recommendation for TAVI

Answer 1

the patient should have a predicted post-TAVI survival of 12 months

Question 2

Life expectancy for aortic stenosis symptomatic with angina

Answer 2

5 years

Question 3

life expectancy for aortic stenosis symptomatic with syncope

Answer 3

3 years

Question 4

life expectancy for aortic stenosis symptomatic with chf

Answer 4

two years

(as opposed to syncope, there have been changes to the LV)

Question 5

who makes the core valve

Answer 5

Medtronic

Question 6

who makes the Sapien valve

Answer 6

Edwards

Question 7

Which valve is balloon expanding

Answer 7

Edwards - Sapien

Question 8

Which valve is self-expanding

Answer 8

Medtronic Core Valve

Question 9

what sizes are available for the Edwards Sapien

Answer 9

20, 23, 26, 29 mm

Question 10

which valve was involved in the PARTNER trial

Answer 10

the Sapien (Edwards)_

Question 11

Partner A study groups

Answer 11

compared TAVR against SAVR in high-risk surgical patients

predicted by a surgical death of 15%

Question 12

PARTNER A results at:

1 month

1 - year

5- year

Answer 12

1 month: TAVR: 3.4 SAVR: 6.6

1 year: TAVR: 24.2%, SAVR: 26.8 (p = 0.001)

5 year: TAVR: 67.8%; SAVR: 62.4 (p = 0.76)

Question 13

Partner B Trial study groups

Answer 13

compared TAVR vs Medical therapy

patients who were not considered suitable for surgery by a combined risk of:

Death + irreversible comorbid > 50%

Question 14

Partner A trial

30-day mortality

Answer 14

1 month: TAVR: 3.4 SAVR: 6.6

Question 15

Partner A trial

1-year mortality

Answer 15

1 year: TAVR: 24.2%, SAVR: 26.8 (p = 0.001)

Question 16

Partner A trial

5-year Mortality

Answer 16

5 year: TAVR: 67.8%; SAVR: 62.4 (p = 0.76)

Question 17

results of the PARTNER C trial at

1 year

5 years

Answer 17

1 year: TAVR 30.7 / OMM: 50.7

5 years: 71.8 / OMM: 93.6

Question 18

sizes available for the CORE valve

Answer 18

23, 26, 29,31 mm

Question 19

what trial compared ballon and self-expandable TAVI valves

in what outcomes was there a difference?

Answer 19

the CHOICE trial

The self-expandable had higher rates of

1. new pacemaker implant
2. Aortic regurgitation
3. valve embolization
4. need for more than one valve

Question 20

Predictors of 30-day mortality after TAVI

Answer 20

1. requirement for open heart surgery
2. Tamponade
3. Vascular sequelae
4. Poor LVEF (<40%) i.e. low flow
5. prior balloon valvuloplasty
6. Diabetes